Literature DB >> 1466978

Highly attenuated poxvirus vectors.

J Tartaglia1, W I Cox, J Taylor, M Perkus, M Riviere, B Meignier, E Paoletti.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1466978     DOI： 10.1089/aid.1992.8.1445

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  13 in total

1.  Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Authors:  José Luis Nájera; Carmen Elena Gómez; Elena Domingo-Gil; María Magdalena Gherardi; Mariano Esteban
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 2.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

Review 3.  Poxvirus vectors as HIV/AIDS vaccines in humans.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Juan Garcia-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

4.  Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Authors:  Carmen Elena Gómez; Beatriz Perdiguero; Jose Luis Nájera; Carlos Oscar S Sorzano; Victoria Jiménez; Rubén González-Sanz; Mariano Esteban
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

5.  Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.

Authors:  Xia Jin; Murugappan Ramanathan; Shady Barsoum; Geoffrey R Deschenes; Lei Ba; James Binley; Daryl Schiller; Daniel E Bauer; Donald C Chen; Arlene Hurley; Lucette Gebuhrer; Raphaelle El Habib; Pierre Caudrelier; Michel Klein; Linqi Zhang; David D Ho; Martin Markowitz
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

6.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

Authors:  J Roth; D Dittmer; D Rea; J Tartaglia; E Paoletti; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

Review 7.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

Review 8.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

9.  Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.

Authors:  Beatriz Perdiguero; Carmen Elena Gómez; Mauro Di Pilato; Carlos Oscar S Sorzano; Julie Delaloye; Thierry Roger; Thierry Calandra; Giuseppe Pantaleo; Mariano Esteban
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

Review 10.  Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.

Authors:  Arwen F Altenburg; Joost H C M Kreijtz; Rory D de Vries; Fei Song; Robert Fux; Guus F Rimmelzwaan; Gerd Sutter; Asisa Volz
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.